Stocks · News reference
Nuvation Bio Announces New Subgroup Analyses From Pivotal TRUST-I And TRUST-II Studies Evaluating IBTROZI In Both TKI- Naïve And TKI-Pretreated Patients With Advanced ROS1+ NSCLC
Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner subgroupsAmong
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Is Nuvation Bio Stock Gaining Thursday?
Nuvation Bio (NUVB) stock jumps 6% after early FDA label update for IBTROZI, highlighting over 4 years of clinical benefit in ROS1+ NSCLC.
Nuvation Bio Says FDA Approves sNDA For IBTROZI, ROS1 Inhibitor For Treatment Of Locally Advanced Or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 monthsNo changes to the safety sections of labeling with longer follow-up and no new safety signals identifiedApproval comes four months
Citizens Reiterates Market Outperform on Nuvation Bio, Maintains $10 Price Target
Citizens analyst Silvan Turkcan reiterates Nuvation Bio (NYSE:NUVB) with a Market Outperform and maintains $10 price target.